Analysis of the Correlation between the Pan-immune Inflammation Value and the Prognosis of Patients with Endometrial Cancer
Abstract
Immune and inflammatory factors influence endometrial cancer outcomes, the pan-immune inflammation value (PIV) shows potential but remains underexplored.
This study aims to evaluate the relationship between preoperative PIV, T cell subtypes, and surgical prognosis in endometrial cancer patients, providing insights for prognostic markers and predictive models. We conducted a prospective observational study involving 101 endometrial cancer patients from August 2022 to August 2024. Based on prognosis within 6 months post-surgery, patients were divided into good and poor prognosis groups. We compared clinical characteristics, inflammatory indices, and T cell immune profiles between the groups.
The mean age of participants was 50.12 years, with 23 patients experiencing a poor prognosis. The poor prognosis group exhibited significantly higher proportions of advanced International Federation of Gynecology and Obstetrics (FIGO) stage, larger tumor diameter, elevated neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), and PIV. Conversely, this group showed lower proportions receiving neoadjuvant chemotherapy, CD4+ T cells, and CD4+CD8+ T cell ratios. Notably, elevated PIV emerged as an independent risk factor for poor prognosis, while increased CD4+ T cell proportion and CD4+CD8+ ratio were protective.
PIV is significantly associated with poor prognosis in endometrial cancer, serving as an independent risk factor. Higher CD4+ T cell counts and CD4+:CD8+ ratios provide protective benefits. The constructed logistic regression model demonstrates strong predictive capability for post-surgical outcomes. However, limitations, including sample size and short follow-up, necessitate further investigation in larger cohorts.
2. Harvey SV, Wentzensen N, Bertrand K, et al. Associations of life course obesity with endometrial cancer in the Epidemiology of Endometrial Cancer Consortium (E2C2). Int J Epidemiol. 2023;52(4):1086-99.
3. Crosbie EJ, Kitson SJ, McAlpine JN, et al. Endometrial cancer. Lancet. 2022;399(10333):1412-28.
4. Borden LE, Locklear TM, Grider DJ, et al. Endometrial cancer characteristics and risk of recurrence. Am J Clin Pathol. 2022;157(1):90-7.
5. Çakır İ, Gülseren V, Özdemir İA, et al. Characteristics of patients with late recurrence endometrial cancer. J Cancer Res Ther. 2024;20(1):232-7.
6. Bhati P, Garg M, Vuppu DP, et al. Unravelling the mystique of recurrence: A comparative analysis of surgical approaches for early-stage endometrial cancer. Eur J Obstet Gynecol Reprod Biol. 2025:308:70-7.
7. Xaligli G, Sancar C, Serin G, et al. Prospective evaluation of uterine artery Doppler for prognosis in endometrial cancer: A tertiary single-center experience. J Obstet Gynaecol Res. 2024;50(10):1808-12.
8. Sahin EA, Toprak S, Sayal HB, et al. Analysis of prognostic factors in grade 3 endometrioid type endometrial carcinoma. Int J Gynaecol Obstet. 2022;159(3):719-26.
9. Restaino S, Poli A, Arcieri M, et al. Molecular classification of endometrial carcinoma on endometrial biopsy: an early prognostic value to guide personalized treatment. Int J Gynecol Cancer. 2024;34(8):1211-1216.
10. Espinós J, Aramendía JM, González-Martín A, et al. Prognostic value of systemic inflammation response indexes in advanced ovarian carcinoma. Clin Transl Oncol. 2024;26(12):3211-7.
11. Wang J, Li H, Xu R, et al. The MLR, NLR, PLR and D-dimer are associated with clinical outcome in lung cancer patients treated with surgery. BMC Pulm Med. 2022;22(1):104.
12. Capozzi VA, Monfardini L, Maglietta G, et al. Pattern of recurrence in endometrial cancer. The murderer always returns to the scene of the crime. Eur J Surg Oncol. 2024;50(3):107985.
13. Oaknin A, Bosse TJ, Creutzberg CL, et al. Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(9):860-77.
14. Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet. 2023;162(2):383-94.
15. Wang QY, Zhong WT, Xiao Y, et al. Pan-immune-inflammation value as a prognostic biomarker for colon cancer and its variation by primary tumor location. World J Gastroenterol. 2024;30(33):3823-36.
16. Tashireva LA, Larionova IV, Ermak NA, et al. Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment. Front Immunol. 2025;15:1523518.
17. Rafiei Sorouri Z, Kabodmehri R, Milani F, et al. Red cell distribution width and mean platelet volume detection in patients with endometrial cancer and endometrial hyperplasia. Health Sci Rep. 2024;7(10):e70109.
18. Mu Z, Wang C, Ye Z, et al. Prognostic values of cancer-associated macrophage-like cells enumeration in metastatic breast cancer. Breast Cancer Res Treat. 2017;165(3):733-41.
19. Sulaiman R, De P, Aske JC, et al. Identification and morphological characterization of circulating cancer-associated macrophage-like cells in endometrial cancers. Cancers (Basel). 2022;14(19):4577.
20. Gulmez A, Coskun H, Koseci T, et al. Effect of microsatellite status and pan-immune-inflammation score on pathological response in patients with stage III stomach cancer. Medicina (Kaunas). 2023;59(9):1625.
21. Kucuk A, Topkan E, Ozkan EE, et al. A high pan-immune-inflammation value before chemoradiotherapy indicates poor outcomes in small-cell lung cancer. Int J Immunopathol Pharmacol. 2023;37:3946320231187759.
22. Su P, An J, Yu L, et al. Peripheral blood lymphocyte subsets as a risk predictor of patients with endometrioid endometrial cancer. J Inflamm Res. 2022;15:6153-63.
23. Tian Y, Zhang Y, Tang X, et al. Analysis of characteristics of peripheral blood lymphocytes in endometrial carcinoma: a single-center study. BMC Cancer. 2024;24(1):1184.
24. Fusagawa M, Tokita S, Murata K, et al. Identification and phenotypic characterization of neoantigen-specific cytotoxic CD4+ T cells in endometrial cancer. Cancer Immunol Res. 2025;13(2):171-84.
25. Matsuo K, Chen L, Klar M, et al. Prognostic performance of the 2023 FIGO staging schema for endometrial cancer. Gynecol Oncol. 2024;187:37-45.
26. Vinklerová P, Ovesná P, Bednaříková M, et al. Does an endometrial cancer diagnosis among asymptomatic patients improve prognosis? Cancers (Basel). 2021;14(1):115.
27. Dessources K, Ferrando L, Zhou QC, et al. Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype. Gynecol Oncol. 2023;171:15-22.
| Files | ||
| Issue | Articles in Press | |
| Section | Original Article(s) | |
| Keywords | ||
| Correlation Endometrial cancer Pan-immune inflammation value Prognosis T cell function | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
